FDA approves Merck’s drug for rare, deadly lung condition

The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.

Previous post Ford sees opportunity for Mustang as competitors abandon V8 engines
Next post GameStop’s demise could come later this decade, analyst says